Dr. Joseph G. Jurcic

Dr. Joseph G. Jurcic, MD, is a widely respected hematologist-oncologist and a leading authority in the treatment of blood and bone marrow cancers. He serves as Professor of Medicine and Director of the Hematologic Malignancies Section at Columbia University Irving Medical Center, where he is also affiliated with NewYork-Presbyterian Hospital. Dr. Jurcic earned his medical degree from the University of Pennsylvania School of Medicine, completed his residency at Barnes-Jewish Hospital, and received fellowship training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. Board-certified in both Hematology and Medical Oncology, he has devoted over three decades to the care of patients with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms.

Dr. Jurcic is widely regarded for his pioneering work in immunotherapy, radioimmunotherapy, and targeted molecular treatments for hematologic malignancies. He has served as Principal Investigator on numerous clinical trials focused on monoclonal antibodies, radiolabeled therapies, and small-molecule inhibitors. His research has led to the development of novel approaches that enhance both efficacy and safety in leukemia care. He has authored more than 80 peer-reviewed publications and book chapters and is frequently invited to speak at national and international oncology conferences. His work has helped advance the use of molecular monitoring to guide treatment decisions and improve long-term outcomes in patients with myeloid diseases.

In addition to his clinical and research leadership, Dr. Jurcic is a dedicated educator and mentor, committed to training the next generation of hematologists and oncologists. He has held leadership roles in major professional organizations and served on editorial boards of leading oncology journals. Consistently recognized as a "Top Doctor" by peers and patient surveys alike, he is known for his compassionate approach, clinical excellence, and commitment to innovation. Through his contributions to research, education, and patient care, Dr. Jurcic continues to shape the evolving landscape of hematologic oncology.